Article

Dr. Richter on Study of Symptom Management in Multiple Myeloma

Author(s):

Joshua Richter, MD

In Partnership With:

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

The management of multiple myeloma has advanced greatly in recent years, extending survival and reducing the instances of skeletal-related events. As the treatment paradigm shifts, increased attention must be brought to symptom and psychological impact on patients, says Richter.

The Living with Cancer patient reported outcome instrument is a tool used by patients to evaluate distress during treatment. In a recent study presented at the 2017 ASH Annual Meeting, investigators sought to determine the incidence of self-reported pain and depression, as well as financial and personal burden. This information was used to evaluate whether these factors impair performance status in patients with multiple myeloma who are receiving outpatient care at a tertiary cancer center.

Related Videos
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jorge E. Cortes, MD
Nicolas Girard, MD
Sunil Adige, MD
Minoo Battiwalla, MD, MS
Samuel J. Klempner, MD
Related Content
Multiple Myeloma - stock.adobe.com
October 18th 2024

Selinexor Receives Approval in South Korea for Multiple Myeloma

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Edmond Chan, MBChB, MD, EMEA of Johnson & Johnson
October 10th 2024

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology